The FDA recently granted accelerated approval to an antibody-drug combination for adults who’ve already received at least 2 treatment regimens for unresectable or metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (ERBB2; formerly HER2/neu).
Marketed as Enhertu, fam-trastuzumab deruxtecan-nxki is an anti-ERBB2 antibody with a cytotoxic topoisomerase I inhibitor attached. It is administered via intravenous infusion. According to the FDA, about 20% of breast cancers have a genetic mutation that results in ERBB2-positive tumors, which are very aggressive.
Voelker R. Another Targeted Therapy for ERBB2-Positive Breast Cancer. JAMA. 2020;323(5):408. doi:10.1001/jama.2020.0222
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: